


Clinical Care Pathway

Clinical Care Pathway for the Risk Stratification and Management of Patients with Nonalcoholic Fatty Liver Disease-Gastroenterology 2021:1-13.
<https://doi.org/10.1053/j.gastro.2021.07.049>

Figure 2: Evaluate for other forms of liver disease



Footnote: 1. Not everyone should be tested for Hep B core antibodies due to high positivity but uncertain clinical significance.

Abbreviations: **HBsAg** = hepatitis B surface antigen, **HBsAb** = hepatitis B surface antibody, **HBcAb** = hepatitis B core antibody, **HCV** = hepatitis C virus, **ANA** = antinuclear antibodies, **AMA** = antimitochondrial antibodies, **ASMA** = anti-smooth muscle antibodies, **A1AT** = Alpha-1 antitrypsin